MoonLake Immunotherapeutics (MLTX) Non Operating Income (2021 - 2022)
MoonLake Immunotherapeutics (MLTX) posted quarterly Non Operating Income of $7774.0 for Q1 2022, down 56.36% year-over-year from $17815.0 in Q1 2021, and up 244.75% quarter-over-quarter from $2255.0 in Q4 2021.
MoonLake Immunotherapeutics (MLTX) Non Operating Income (2021 - 2022) Analysis & Trends
MoonLake Immunotherapeutics' Non Operating Income history runs 2 years deep, the most recent figure standing at $7774.0 for Q1 2022.
- In Q1 2022, Non Operating Income fell 56.36% year-over-year to $7774.0; the TTM figure through Mar 2022 stood at $17650.0 (changed N/A YoY), while the FY2021 annual figure was $27691.0, up 85.63% from the prior year.
- Non Operating Income for Q1 2022 stood at $7774.0, up from $2255.0 in the prior quarter.
- The five-year high for Non Operating Income was $17815.0 in Q1 2021, with the low at $1481.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 7,774.00 |
| Dec 31, 2021 | 2,255.00 |
| Sep 30, 2021 | 1,481.00 |
| Jun 30, 2021 | 6,140.00 |
| Mar 31, 2021 | 17,815.00 |